Rapt Therapeutics (RAPT) Expected to Announce Quarterly Earnings on Thursday

Key Points

• Rapt Therapeutics is set to announce its Q2 2025 earnings on August 14th, with analysts predicting a loss of ($0.68) per share.
• The company recently received multiple upgrades from analysts, including a "strong-buy" rating and a price target of $31 from Lifesci Capital.
• Invesco Ltd. significantly increased its stake in Rapt Therapeutics by 411.7%, reflecting growing institutional interest in the company.

Rapt Therapeutics (NASDAQ:RAPT - Get Free Report) is anticipated to issue its Q2 2025 quarterly earnings data before the market opens on Thursday, August 14th. Analysts expect the company to announce earnings of ($0.68) per share for the quarter.

Rapt Therapeutics (NASDAQ:RAPT - Get Free Report) last announced its quarterly earnings data on Thursday, May 8th. The company reported ($0.64) EPS for the quarter, beating the consensus estimate of ($2.48) by $1.84. On average, analysts expect Rapt Therapeutics to post $-2 EPS for the current fiscal year and $-1 EPS for the next fiscal year.

Rapt Therapeutics Trading Down 1.1%

NASDAQ:RAPT opened at $9.99 on Thursday. Rapt Therapeutics has a twelve month low of $5.67 and a twelve month high of $26.56. The company has a market cap of $165.23 million, a price-to-earnings ratio of -0.52 and a beta of 0.01. The stock has a fifty day simple moving average of $9.34 and a 200-day simple moving average of $8.79.

Wall Street Analysts Forecast Growth

Several research analysts recently commented on RAPT shares. Lifesci Capital raised shares of Rapt Therapeutics to a "strong-buy" rating and set a $31.00 price target on the stock in a research note on Tuesday, July 22nd. HC Wainwright raised their target price on shares of Rapt Therapeutics to $27.00 and gave the stock a "buy" rating in a research report on Thursday, July 10th. UBS Group lowered their price target on Rapt Therapeutics from $16.00 to $8.00 and set a "neutral" rating for the company in a report on Thursday, May 22nd. JPMorgan Chase & Co. raised Rapt Therapeutics from an "underweight" rating to a "neutral" rating and set a $14.00 price objective on the stock in a research note on Wednesday, July 30th. Finally, Wall Street Zen raised Rapt Therapeutics from a "sell" rating to a "hold" rating in a research report on Saturday, July 26th. Five analysts have rated the stock with a hold rating, two have given a buy rating and one has given a strong buy rating to the company's stock. According to MarketBeat.com, the company currently has an average rating of "Moderate Buy" and a consensus target price of $20.57.

Institutional Trading of Rapt Therapeutics

An institutional investor recently raised its position in Rapt Therapeutics stock. Invesco Ltd. increased its stake in shares of Rapt Therapeutics (NASDAQ:RAPT - Free Report) by 411.7% in the first quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 58,901 shares of the company's stock after purchasing an additional 47,391 shares during the quarter. Invesco Ltd.'s holdings in Rapt Therapeutics were worth $72,000 as of its most recent SEC filing. Hedge funds and other institutional investors own 99.09% of the company's stock.

Rapt Therapeutics Company Profile

RAPT Therapeutics, Inc, a clinical-stage immunology-based biopharmaceutical company, focuses on discovery, development, and commercialization of oral small molecule therapies for patients with unmet needs in oncology and inflammatory diseases in the United States. The company's lead inflammation drug candidate is zelnecirnon (RPT193), a C-C motif chemokine receptor 4 (CCR4) antagonist that selectively inhibit the migration of type 2 T helper cells into inflamed tissues.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.